Comparison of Participants Who Received a CanGaroo® Envelope, TYRX™ Envelope, or no Envelope During CIED Implantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-02

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to gather information on participants returning at time of CIED change-out or revision who underwent a device implantation with either a CanGaroo® envelope, TYRX™ envelope, or no envelope.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Retrospective Experience Of CIED Implantation

NCT04351269

Cardiac Disease Heart Failure Coronary Artery Disease

COMPLETED

CanGaroo® Registry Study

NCT04846127

Arrhythmias, Cardiac

COMPLETED

Performance of the CARDIOGARD Cannula

NCT02764645

Heart Valve Diseases Coronary Artery Disease

UNKNOWN NA

EluPro Antibiotic-Eluting BioEnvelope Registry

NCT06854081

Cardiac Arrhythmias

RECRUITING

World-wide Randomized Antibiotic Envelope Infection Prevention Trial

NCT02277990

CIED Related Infection

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This multi-center study will enroll up to approximately 100 participants who have undergone one or more implantations of a CIED with either CanGaroo®, TYRX™, or no envelope (up to approximately 30-35 participants per cohort) and are returning for a CIED change-out or revision procedure at least 4 months or longer from their prior procedure.

Once enrolled, each participant will have their medical history data collected (baseline demographics, medical history, prior CIED exchanges/revisions, and post implant clinical events). Prior to the scheduled change-out/revision procedure, there will be an assessment of the current healed implant site skin incision independently by both the participant and investigator using the Patient and Observer Scar Assessment Scale (POSAS), as well as photographs taken of the current skin scar.

During the change-out/revision procedure, additional investigator assessments will include photographic documentation of CIED implant pocket lining, classification of the extent of lead adhesions in the implant pocket, and biopsies of the anterior and posterior capsule walls for histologic analysis. Procedural details and any complications/AEs that occur during the change-out/revision procedure will also be captured.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CanGaroo Envelope

Participants who received a CanGaroo envelope during CIED implantation

CIED envelope

Intervention Type DEVICE

Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.

TYRX Envelope

Participants who received a TYRX envelope during CIED implantation

CIED envelope

Intervention Type DEVICE

Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.

No Envelope

Participants who did not receive an envelope during CIED implantation

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CIED envelope

Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants who previously underwent one or more prior CIED implantations utilizing a CanGaroo® envelope, TYRX™ envelope, or no envelope and are returning for a CIED change-out or revision procedure at least 4 months or longer from their prior procedure.
2. The following possible scenarios would be eligible for enrollment:

a. One prior CIED Implant: i. No envelope ii. CanGaroo® envelope iii. TYRX™ envelope b. Multiple prior CIED Implants (envelope type should remain the same for each participant throughout their implant history): i. No envelope → no envelope ii. No envelope → CanGaroo® envelope iii. No envelope → TYRX™ envelope iv. CanGaroo® envelope → CanGaroo® envelope v. TYRX™ envelope → TYRX™ envelope vi. No envelope → CanGaroo® envelope → CanGaroo® envelope vii. No envelope → no envelope → CanGaroo® envelope viii. No envelope → TYRX™ envelope → TYRX™ envelope ix. No envelope → no envelope → TYRX™ envelope
3. Participants aged 18 years or older at time of enrollment.
4. Participant is able and agrees to provide written informed consent and use of PHI.
5. Participants for whom prior CIED implant history information can be obtained.

Exclusion Criteria

1. Active infection involving the CIED implant site (clinical diagnosis of an active infection at the time of change-out/revision procedure).
2. Participants under the age of 18 at time of enrollment.
3. Participants with a history of multiple prior CIED implants over time using more than one type of envelope will be excluded as well as participants with a history of one type of envelope use, but the current pocket does not have an envelope. Scenarios that would be excluded:

1. CanGaroo® envelope → TYRX™ envelope
2. TYRX™ envelope → CanGaroo® envelope
3. CanGaroo® envelope - no envelope
4. TYRX™ envelope → no envelope
5. No envelope → CanGaroo® envelope → no envelope
6. No envelope → TYRX™ envelope → no envelope
7. No envelope → CanGaroo® envelope → TYRX™ envelope
8. No envelope → TYRX™ envelope → CanGaroo® envelope
9. CanGaroo® envelope → no envelope → TYRX™ envelope
10. TYRX™ envelope → no envelope → CanGaroo® envelope
11. CanGaroo® envelope → TYRX™ envelope → no envelope
12. TYRX™ envelope → CanGaroo® envelope → no envelope
13. CanGaroo® envelope → CanGaroo® envelope → no envelope
14. TYRX™ envelope → TYRX™ envelope → no envelope
4. Participants undergoing a change-out or revision procedure less than 4 months from their prior procedure.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No